Eisai Inc. and Morphotek Inc. Announce Initiation of MORAb-022 Study in Europe for the Treatment of Inflammatory Disease

WOODCLIFF LAKE, N.J. & EXTON, Pa.--(BUSINESS WIRE)--Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.